Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVENUE-2: Acalabrutinib + Venetoclax for Relapsed/Refractory CLL/SLL
NCT04941716Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1), venetoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Fred Hutchinson Cancer Center. Started May 2023; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04941716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941716.